PBAC's latest decision on Ferric derisomaltose: Deferred (2019). Considered for Treatment of iron deficiency in adults when oral iron preparations are ineffective or cannot be used, or where there is a clinical need to deliver iron rapidly.
PBAC outcome
Deferred
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2018
Submissions
2
2018 → 2019
Eligible population
Adults with iron deficiency requiring intravenous iron when oral iron preparations are ineffective or cannot be used, or where there is a clinical need to deliver iron rapidly.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
ferric carboxymaltose
Economic model
Cost-minimisation
ICER note
Minor submission; no economic comparison presented. Cost-minimisation basis relative to ferric carboxymaltose.
Risk sharing
Risk-sharing arrangement in place — Risk Sharing Arrangement (RSA) for iron deficiency anaemia (IDA) applies to ferric carboxymaltose and ferric derisomaltose. New term for the Deed of Agreement needs to be renegotiated; subsidisation caps require updating.